Collagen Solutions, the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, has been invited to participate as an industrial collaborator for an upcoming Horizon 2020 (H2020) project.
The wholly grant-funded project addresses a pressing clinical need using cell-based tissue regeneration techniques.
Collagen Solutions is already a consortium partner on an existing H2020 programme to develop formulations of collagen for the delivery of therapeutic moieties for the treatment of Parkinson's Disease.
The project is expected to begin in early 2017 and will run for approximately five years, over which Collagen Solutions will receive approximately €500,000 of European Union (EU) funding, and is subject to a formalised Grant Agreement between the consortium members and the European Commission.
At 8:07am: (LON:COS) Collagen Solutions PLC ORD 1P share price was 0p at 8.63p